Strategic Outlook toward 2030: Japan's research for allergy and immunology – Secondary publication
Strategic Outlook toward 2030: Japan's Research for Allergy and Immunology (Strategy 2030) is the national research strategy based on Japan's Basic Law on Measures Against Allergic Diseases, a first of its kind worldwide. This strategy was established by a multi-disciplinary committee cons...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-10-01
|
Series: | Allergology International |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1323893020300563 |
id |
doaj-692f23b816fc48c98e98c05eaf395a3f |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Takeya Adachi Keigo Kainuma Koichiro Asano Masayuki Amagai Hiroyuki Arai Ken J. Ishii Komei Ito Eiichi Uchio Motohiro Ebisawa Mitsuhiro Okano Kenji Kabashima Kenji Kondo Satoshi Konno Hidehisa Saeki Mariko Sonobe Mizuho Nagao Nobuyuki Hizawa Atsuki Fukushima Shigeharu Fujieda Kenji Matsumoto Hideaki Morita Kazuhiko Yamamoto Akemi Yoshimoto Mayumi Tamari |
spellingShingle |
Takeya Adachi Keigo Kainuma Koichiro Asano Masayuki Amagai Hiroyuki Arai Ken J. Ishii Komei Ito Eiichi Uchio Motohiro Ebisawa Mitsuhiro Okano Kenji Kabashima Kenji Kondo Satoshi Konno Hidehisa Saeki Mariko Sonobe Mizuho Nagao Nobuyuki Hizawa Atsuki Fukushima Shigeharu Fujieda Kenji Matsumoto Hideaki Morita Kazuhiko Yamamoto Akemi Yoshimoto Mayumi Tamari Strategic Outlook toward 2030: Japan's research for allergy and immunology – Secondary publication Allergology International Allergy Immunology Japan MHLW Strategy |
author_facet |
Takeya Adachi Keigo Kainuma Koichiro Asano Masayuki Amagai Hiroyuki Arai Ken J. Ishii Komei Ito Eiichi Uchio Motohiro Ebisawa Mitsuhiro Okano Kenji Kabashima Kenji Kondo Satoshi Konno Hidehisa Saeki Mariko Sonobe Mizuho Nagao Nobuyuki Hizawa Atsuki Fukushima Shigeharu Fujieda Kenji Matsumoto Hideaki Morita Kazuhiko Yamamoto Akemi Yoshimoto Mayumi Tamari |
author_sort |
Takeya Adachi |
title |
Strategic Outlook toward 2030: Japan's research for allergy and immunology – Secondary publication |
title_short |
Strategic Outlook toward 2030: Japan's research for allergy and immunology – Secondary publication |
title_full |
Strategic Outlook toward 2030: Japan's research for allergy and immunology – Secondary publication |
title_fullStr |
Strategic Outlook toward 2030: Japan's research for allergy and immunology – Secondary publication |
title_full_unstemmed |
Strategic Outlook toward 2030: Japan's research for allergy and immunology – Secondary publication |
title_sort |
strategic outlook toward 2030: japan's research for allergy and immunology – secondary publication |
publisher |
Elsevier |
series |
Allergology International |
issn |
1323-8930 |
publishDate |
2020-10-01 |
description |
Strategic Outlook toward 2030: Japan's Research for Allergy and Immunology (Strategy 2030) is the national research strategy based on Japan's Basic Law on Measures Against Allergic Diseases, a first of its kind worldwide. This strategy was established by a multi-disciplinary committee consisting of administrators of the Ministry of Health, Labour and Welfare of Japan, young and senior experts from various research societies and associations, and representatives of patient and public groups. Whereas the issues of transition, integration, and international collaboration have yet to be solved in this research realm in Japan, identification of unmet needs, digitization of information and transparent procedures, and strategic planning for complex problems (a process dubbed MIERUKA by the Toyota Way) are crucial to share and tackle the same vision and goals. The committee developed three specific actions focusing on preemptive treatment, interdisciplinarity and internationality, and life stage. The real success of Strategy 2030 is made by the spontaneous contributions of doctors, dentists, veterinarians, and other medical professionals; basic and clinical research scientists, research supporters, and pharmaceutical/medical device companies; manufacturers of food, healthcare, and home appliances; and patients, their families, and the public. The hope is to establish a stable society in which people can live long, healthy lives, as free as possible from allergic and immunological diseases, at each individual life stage. This article is based on a Japanese review first reported in Arerugi, introduces the developmental process and details of Strategy 2030. |
topic |
Allergy Immunology Japan MHLW Strategy |
url |
http://www.sciencedirect.com/science/article/pii/S1323893020300563 |
work_keys_str_mv |
AT takeyaadachi strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT keigokainuma strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT koichiroasano strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT masayukiamagai strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT hiroyukiarai strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT kenjishii strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT komeiito strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT eiichiuchio strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT motohiroebisawa strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT mitsuhirookano strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT kenjikabashima strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT kenjikondo strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT satoshikonno strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT hidehisasaeki strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT marikosonobe strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT mizuhonagao strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT nobuyukihizawa strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT atsukifukushima strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT shigeharufujieda strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT kenjimatsumoto strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT hideakimorita strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT kazuhikoyamamoto strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT akemiyoshimoto strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication AT mayumitamari strategicoutlooktoward2030japansresearchforallergyandimmunologysecondarypublication |
_version_ |
1724458129176920064 |
spelling |
doaj-692f23b816fc48c98e98c05eaf395a3f2020-11-25T03:58:18ZengElsevierAllergology International1323-89302020-10-01694561570Strategic Outlook toward 2030: Japan's research for allergy and immunology – Secondary publicationTakeya Adachi0Keigo Kainuma1Koichiro Asano2Masayuki Amagai3Hiroyuki Arai4Ken J. Ishii5Komei Ito6Eiichi Uchio7Motohiro Ebisawa8Mitsuhiro Okano9Kenji Kabashima10Kenji Kondo11Satoshi Konno12Hidehisa Saeki13Mariko Sonobe14Mizuho Nagao15Nobuyuki Hizawa16Atsuki Fukushima17Shigeharu Fujieda18Kenji Matsumoto19Hideaki Morita20Kazuhiko Yamamoto21Akemi Yoshimoto22Mayumi Tamari23Japan Agency for Medical Research and Development (AMED), Tokyo, Japan; International Human Frontier Science Program Organization (HFSPO), Strasbourg, France; CNRS UPR 3572, Institut de Biologie Moléculaire et Cellulaire (IBMC), Université de Strasbourg, Strasbourg, France; Corresponding author. International Human Frontier Science Program Organization (HFSPO), 12 Quai Saint-Jean 67000 Strasbourg, FranceInstitute for Clinical Research, National Hospital Organization, Mie National Hospital, Mie, JapanDivision of Pulmonary Medicine, Department of Medicine, Tokai University, School of Medicine, Kanagawa, JapanDepartment of Dermatology, Keio University School of Medicine, Tokyo, JapanPharmaceuticals and Medical Devices Agency (PMDA), Tokyo, JapanDepartment of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, JapanDepartment of Allergy, Aichi Children's Health and Medical Center, Aichi, JapanDepartment of Ophthalmology, Fukuoka University School of Medicine, Fukuoka, JapanClinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Kanagawa, JapanDepartment of Otorhinolaryngology, International University of Health and Welfare School of Medicine, Chiba, JapanDepartment of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JapanDepartment of Otolaryngology and Head and Neck Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, JapanDepartment of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, JapanDepartment of Cutaneous and Mucosal Pathophysiology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanJapanese Mother's Society for Allergy Care (JMSAC), Kanagawa, JapanInstitute for Clinical Research, National Hospital Organization, Mie National Hospital, Mie, JapanDivision of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, JapanDepartment of Ophthalmology, Kochi Medical School, Kochi, JapanDepartment of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, University of Fukui, Fukui, JapanDepartment of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, JapanDepartment of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, JapanCenter for Integrative Medical Sciences, The Institute of Physical and Chemical Research (RIKEN), Kanagawa, JapanKyodo News, Tokyo, JapanDivision of Molecular Genetics, The Jikei University School of Medicine, Research Center for Medical Science, Tokyo, Japan; Corresponding author. Division of Molecular Genetics, The Jikei University School of Medicine, Research Center for Medical Science, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-8461, Japan.Strategic Outlook toward 2030: Japan's Research for Allergy and Immunology (Strategy 2030) is the national research strategy based on Japan's Basic Law on Measures Against Allergic Diseases, a first of its kind worldwide. This strategy was established by a multi-disciplinary committee consisting of administrators of the Ministry of Health, Labour and Welfare of Japan, young and senior experts from various research societies and associations, and representatives of patient and public groups. Whereas the issues of transition, integration, and international collaboration have yet to be solved in this research realm in Japan, identification of unmet needs, digitization of information and transparent procedures, and strategic planning for complex problems (a process dubbed MIERUKA by the Toyota Way) are crucial to share and tackle the same vision and goals. The committee developed three specific actions focusing on preemptive treatment, interdisciplinarity and internationality, and life stage. The real success of Strategy 2030 is made by the spontaneous contributions of doctors, dentists, veterinarians, and other medical professionals; basic and clinical research scientists, research supporters, and pharmaceutical/medical device companies; manufacturers of food, healthcare, and home appliances; and patients, their families, and the public. The hope is to establish a stable society in which people can live long, healthy lives, as free as possible from allergic and immunological diseases, at each individual life stage. This article is based on a Japanese review first reported in Arerugi, introduces the developmental process and details of Strategy 2030.http://www.sciencedirect.com/science/article/pii/S1323893020300563AllergyImmunologyJapanMHLWStrategy |